Food may not be the major cause of hyperactivity in children. Genetics, brain function and parental actions such as smoking may be just as important.

Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today presented the results of a phase III pivotal study in which VYVANSE demonstrated significant improvements in Attention Deficit Hyperactivity Disorder (ADHD) symptoms in adults and met all safety and efficacy endpoints.

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced findings from a new data analysis that was conducted to examine treatment differences with DAYTRANA™ (methylphenidate transdermal system) between boys and girls aged 6 to 12 years with Attention Deficit Hyperactivity Disorder (ADHD).

Shire plc(LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, presented today at a major scientific meeting findings from analyses of pivotal trial results of INTUNIV, a selective alpha-2A-agonist. This compound is an investigational once-daily medication, which is being evaluated for the treatment of the symptoms of Attention Deficit Hyperactivity Disorder (ADHD).

A new UCLA study shows that only about half of children diagnosed with attention-deficit hyperactivity disorder, or ADHD, exhibit the cognitive defects commonly associated with the condition.

Nationally recognized Attention Deficit Hyperactivity Disorder (ADHD) authority Russell Barkley, Ph.D., has embarked on a national speaking tour to discuss the symptoms of ADHD in adults and the potentially serious consequences these symptoms may have on the life of an adult living with this disorder.

Some patients with Attention Deficit Hyperactivity Disorder (ADHD) in Western Australia are dispensed more stimulant medication than they need.

Researchers have also employed this technology for use in special 'night lights'
Scientists at John Carroll University, working in its Lighting Innovations Institute, have developed an affordable accessory that appears to reduce the symptoms of ADHD. Their discovery also has also been shown to improve sleep patterns among people who have difficulty falling asleep.

Adults with Attention Deficit Hyperactivity Disorder (ADHD) treated with CONCERTA® OROS® methylphenidate HCl Extended-release Tablets showed significant improvements in ADHD symptom management compared to adults taking placebo, according to study results presented today at a major psychiatric medical meeting.

Adults with attention-deficit hyperactivity disorder (ADHD) show a blunted response to the drug methylphenidate (Ritalin), which increases brain dopamine levels, according to a report in the August issue of Archives of General Psychiatry, one of the JAMA/Archives journals. This suggests that dopamine dysfunction may be involved with ADHD symptoms and may contribute to substance abuse that often occurs simultaneously.

In the first known study of its kind, an article published in the August 1st issue of the journal SLEEP finds that children with attention deficit hyperactivity disorder (ADHD), and whose sleep efficiency is poor, experience significant improvement on some measures of the Continuous Performance Test (CPT) if they are treated with methylphenidate (MPH).

Shire plc announced that DAYTRANAâ„¢ (methylphenidate transdermal system), its Attention Deficit Hyperactivity Disorder (ADHD) patch, had significant efficacy in reducing the symptoms of ADHD in both male and female children aged 6 to 12 years, according to clinical trial results reported at the American Psychiatric Association (APA) annual meeting in San Diego.